İkBal İnAnlı
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
İkBal İnAnlı has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Medine Giynas Ayhan
Department of Psychiatry, Beyhekim Training and Research Hospital, University of Health Sciences, Konya, Türkiye
4 shared publications - Hazel Demiröz Öztürk
Department of Psychiatry, Sakarya Training and Research Hospital, Sakarya, Türkiye
2 shared publications Adem Küçük
1 shared publication- Ali Metehan Caliskan
Department of Psychiatry, University of Health Sciences, Konya Education and Research Hospital, Konya
1 shared publication - Erkan Cure
İstinye University
1 shared publication - Hüseyin Erdal
Aksaray University
1 shared publication
Latest Publications
- 24 September 2026
- Published by Elsevier in Psychiatry Research
- Vol. 366
Effects of Lithium Treatment on Renal Function in Bipolar Disorder: A Retrospective Cohort Study
- 24 September 2026
- Published by Elsevier in Psychiatry Research
- Vol. 366
Effects of Lithium Treatment on Renal Function in Bipolar Disorder: A Retrospective Cohort Study
- Open Access
- 3 September 2026
- Published by MDPI AG in Brain Sciences
- Vol. 16 (9) , 943
Subsyndromal Depressive Symptoms in Bipolar Disorder: Associations with Functioning, Internalized Stigma, Impulsivity, and Anxiety
Backgrounds/Objectives: Subsyndromal depressive symptoms are common during inter-episode periods in bipolar disorder and have been associated with functional impairment. This study aimed to examine their clinical and psychosocial correlates across multiple domains and to evaluate depressive symptom severity from both categorical and dimensional perspectives. Methods: This cross-sectional study included 133 outpatients with bipolar I disorder who had experienced no syndromal mood episode during the preceding six months. Patients were classified as having subsyndromal depressive symptoms (n = 61; HDRS 8–14 and YMRS < 8) or as euthymic (n = 72; HDRS < 8 and YMRS < 8). Clinical characteristics, functioning, impulsivity, internalized stigma, and anxiety were assessed. Results: The subsyndromal depressive group had higher total and depressive episode counts and more frequent histories of antidepressant-induced manic switch and suicide attempt than the euthymic group (all p < 0.05). They also showed lower functioning and higher impulsivity, internalized stigma, and anxiety (all p < 0.05). Within the subsyndromal depressive group, depressive symptom severity was associated with the number of depressive episodes and specific domains of functioning, impulsivity, internalized stigma, and anxiety. Conclusions: Subsyndromal depressive symptoms were associated with clinically relevant differences across multiple clinical and psychosocial domains during inter-episode periods in bipolar I disorder. The associations observed across specific domains also support considering depressive symptom severity dimensionally alongside categorical assessment.
- 3 September 2026
- Published by MDPI AG in Brain Sciences
- Vol. 16 (9) , 943
Open AccessSubsyndromal Depressive Symptoms in Bipolar Disorder: Associations with Functioning, Internalized Stigma, Impulsivity, and Anxiety
Backgrounds/Objectives: Subsyndromal depressive symptoms are common during inter-episode periods in bipolar disorder and have been associated with functional impairment. This study aimed to examine their clinical and psychosocial correlates across multiple domains and to evaluate depressive symptom severity from both categorical and dimensional perspectives. Methods: This cross-sectional study included 133 outpatients with bipolar I disorder who had experienced no syndromal mood episode during the preceding six months. Patients were classified as having subsyndromal depressive symptoms (n = 61; HDRS 8–14 and YMRS < 8) or as euthymic (n = 72; HDRS < 8 and YMRS < 8). Clinical characteristics, functioning, impulsivity, internalized stigma, and anxiety were assessed. Results: The subsyndromal depressive group had higher total and depressive episode counts and more frequent histories of antidepressant-induced manic switch and suicide attempt than the euthymic group (all p < 0.05). They also showed lower functioning and higher impulsivity, internalized stigma, and anxiety (all p < 0.05). Within the subsyndromal depressive group, depressive symptom severity was associated with the number of depressive episodes and specific domains of functioning, impulsivity, internalized stigma, and anxiety. Conclusions: Subsyndromal depressive symptoms were associated with clinically relevant differences across multiple clinical and psychosocial domains during inter-episode periods in bipolar I disorder. The associations observed across specific domains also support considering depressive symptom severity dimensionally alongside categorical assessment.
- 27 April 2026
- Published by SAGE Publications in Journal of Investigative Medicine
Serum calprotectin levels and other inflammation biomarkers in manic episode of bipolar disorder: A comparative study
Previous studies suggest that inflammation may be implicated in the pathogenesis of acute mania in bipolar disorder (BD). This case–control study aimed to evaluate the serum levels of calprotectin, a neutrophil activation biomarker, along with other complete blood count (CBC)-derived inflammation markers in the manic episode of BD compared to controls and to determine any relationship with the severity of manic symptoms. Fifty manic patients and 50 healthy controls matched for age, sex, and body mass index were included in the study. The serum calprotectin levels were measured by ELISA. Pan-immune inflammation value (PIV), systemic immune-inflammatory index (SII), systemic immune-inflammatory response index (SIRI), neutrophil/lymphocyte ratio (NLR), and platelet/lymphocyte ratio (PLR) were also calculated using CBC. The Young Mania Rating Scale (YMRS) was used to assess the severity of clinical symptoms. The level of serum calprotectin was 1.67 ± 0.69 ng/ml in the patient group and 0.95 ± 0.25 ng/ml in the control group ( p < 0.001). The inflammatory markers PIV, SII, SIRI, and NLR, but not PLR ( p = 0.450), were significantly higher in the patient group compared to the control group ( p ≤ 0.001 for all comparisons). The area under curve of the calprotectin and NLR score for manic episode were 0.852 and 0.809, respectively. A moderate positive correlation was found between calprotectin level and severity of manic symptoms. Our findings highlight the role of inflammation in the pathophysiology of BD during the manic episode and suggest that calprotectin and NLR can serve as inflammation markers to distinguish manic episode of BD patients from controls.
- 27 April 2026
- Published by SAGE Publications in Journal of Investigative Medicine
Serum calprotectin levels and other inflammation biomarkers in manic episode of bipolar disorder: A comparative study
Previous studies suggest that inflammation may be implicated in the pathogenesis of acute mania in bipolar disorder (BD). This case–control study aimed to evaluate the serum levels of calprotectin, a neutrophil activation biomarker, along with other complete blood count (CBC)-derived inflammation markers in the manic episode of BD compared to controls and to determine any relationship with the severity of manic symptoms. Fifty manic patients and 50 healthy controls matched for age, sex, and body mass index were included in the study. The serum calprotectin levels were measured by ELISA. Pan-immune inflammation value (PIV), systemic immune-inflammatory index (SII), systemic immune-inflammatory response index (SIRI), neutrophil/lymphocyte ratio (NLR), and platelet/lymphocyte ratio (PLR) were also calculated using CBC. The Young Mania Rating Scale (YMRS) was used to assess the severity of clinical symptoms. The level of serum calprotectin was 1.67 ± 0.69 ng/ml in the patient group and 0.95 ± 0.25 ng/ml in the control group ( p < 0.001). The inflammatory markers PIV, SII, SIRI, and NLR, but not PLR ( p = 0.450), were significantly higher in the patient group compared to the control group ( p ≤ 0.001 for all comparisons). The area under curve of the calprotectin and NLR score for manic episode were 0.852 and 0.809, respectively. A moderate positive correlation was found between calprotectin level and severity of manic symptoms. Our findings highlight the role of inflammation in the pathophysiology of BD during the manic episode and suggest that calprotectin and NLR can serve as inflammation markers to distinguish manic episode of BD patients from controls.
- 7 March 2025
- Published by Taylor & Francis in Journal of Loss and Trauma
- Vol. 30 (8) , 1246-1267
Predictors of Posttraumatic Stress Disorder in Patients with COVID-19: A Prospective Study
- 7 March 2025
- Published by Taylor & Francis in Journal of Loss and Trauma
- Vol. 30 (8) , 1246-1267
Predictors of Posttraumatic Stress Disorder in Patients with COVID-19: A Prospective Study
- Open Access
- 7 March 2025
- Published by Korean College of Neuropsychopharmacology in Clinical Psychopharmacology and Neuroscience
- Vol. 23 (3) , 391-399
Evaluation of Pan-immune Inflammation Value and Systemic Immune Inflammation Index in Different Mood Episodes of Bipolar Disorder
Medine Gıynaş Ayhan, Hazel Demiröz Öztürk, İkbal İnanlı. Clin Psychopharmacol Neurosci 2025;23:391-9. https://doi.org/10.9758/cpn.24.1260
- 7 March 2025
- Published by Korean College of Neuropsychopharmacology in Clinical Psychopharmacology and Neuroscience
- Vol. 23 (3) , 391-399
Open AccessEvaluation of Pan-immune Inflammation Value and Systemic Immune Inflammation Index in Different Mood Episodes of Bipolar Disorder
Medine Gıynaş Ayhan, Hazel Demiröz Öztürk, İkbal İnanlı. Clin Psychopharmacol Neurosci 2025;23:391-9. https://doi.org/10.9758/cpn.24.1260
- 1 February 2024
- Published by Bentham Science Publishers Ltd. in Current Psychiatry Research and Reviews
- Vol. 20 (1) , 70-73
Lithium-induced Discontinuation Refractoriness: A Report of Two Cases
Introduction: Lithium is an effective mood stabilizer. In patients with bipolar disorder using long-term lithium, discontinuation of lithium can lead to severe clinical outcomes such as lithium-induced discontinuation refractoriness. We present two clinical cases of lithium- induced discontinuation refractoriness. Case Presentation: We present two female patients with a good long-term response to lithium. Both patients did not have a mood episode for many years and had residual symptoms. The first patient discontinued lithium voluntarily, while the second patient discontinued lithium treatment due to impaired thyroid function. Lithium was added to the treatment of both patients, but lithium-induced discontinuation refractoriness developed. Conclusion: It should be kept in mind that it may develop refractoriness to lithium when deciding to discontinue lithium treatment, especially in patients with a good long-term response to lithium.
- 1 February 2024
- Published by Bentham Science Publishers Ltd. in Current Psychiatry Research and Reviews
- Vol. 20 (1) , 70-73
Lithium-induced Discontinuation Refractoriness: A Report of Two Cases
Introduction: Lithium is an effective mood stabilizer. In patients with bipolar disorder using long-term lithium, discontinuation of lithium can lead to severe clinical outcomes such as lithium-induced discontinuation refractoriness. We present two clinical cases of lithium- induced discontinuation refractoriness. Case Presentation: We present two female patients with a good long-term response to lithium. Both patients did not have a mood episode for many years and had residual symptoms. The first patient discontinued lithium voluntarily, while the second patient discontinued lithium treatment due to impaired thyroid function. Lithium was added to the treatment of both patients, but lithium-induced discontinuation refractoriness developed. Conclusion: It should be kept in mind that it may develop refractoriness to lithium when deciding to discontinue lithium treatment, especially in patients with a good long-term response to lithium.
- Open Access
- 18 March 2021
- Published by IMR Press in Anadolu Psikiyatri Dergisi-Anatolian Journal Of Psychiatry
- Vol. 22 (2) , 118-119
Delirium after pregabalin withdrawal: case report
Pregabalin is a γ-amino butyric acid analogue drug that is used in fibromyalgia, neuropathic pain associated with diabetic peripheral neuropathy, spinal cord injury, and postherpetic neuralgia. Symptoms reported in association with pregabalin withdrawal include insomnia, gastrointestinal distress, tachycardia, and headache. This case report describes a 68-year-old patient who developed delirium after experiencing pregabalin withdrawal. Clinicians should be aware of the possibility of pregabalin withdrawal delirium.
- 18 March 2021
- Published by IMR Press in Anadolu Psikiyatri Dergisi-Anatolian Journal Of Psychiatry
- Vol. 22 (2) , 118-119
Open AccessDelirium after pregabalin withdrawal: case report
Pregabalin is a γ-amino butyric acid analogue drug that is used in fibromyalgia, neuropathic pain associated with diabetic peripheral neuropathy, spinal cord injury, and postherpetic neuralgia. Symptoms reported in association with pregabalin withdrawal include insomnia, gastrointestinal distress, tachycardia, and headache. This case report describes a 68-year-old patient who developed delirium after experiencing pregabalin withdrawal. Clinicians should be aware of the possibility of pregabalin withdrawal delirium.
- 15 March 2011
- Published by Turk Noropsikiyatri Dernegi in Archives of Neuropsychiatry
- Vol. 48 (1) , 1
ANKİLOZAN SPONDİLİT HASTALARINDA PSİKİYATRİK BELİRTİLERİN, YETİYİTİMİ VE YAŞAM KALİTESİ İLE İLİŞKİSİ
- 15 March 2011
- Published by Turk Noropsikiyatri Dernegi in Archives of Neuropsychiatry
- Vol. 48 (1) , 1
ANKİLOZAN SPONDİLİT HASTALARINDA PSİKİYATRİK BELİRTİLERİN, YETİYİTİMİ VE YAŞAM KALİTESİ İLE İLİŞKİSİ